Sumitomo Pharma Co., Ltd.

4506

JP3495000006

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
410 ^JPY	+2.50%		+5.40%	-12.02%

Apr. 22	Lull in Geopolitical Tensions Lifts Asian Stock Markets	MT
Apr. 17	Jefferies Adjusts Sumitomo Pharma’s Price Target to 420 Yen From 520 Yen, Keeps at Hold	MT

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024

October 31, 2023 at 12:30 am EDT

Sumitomo Pharma Co., Ltd. provided dividend guidance for the second quarter and full year of fiscal year ending March 31, 2024. For the period, the company expects to pay dividend of JPY 0.00 against JPY 14.00 a year ago.

For the year, the company expects to pay dividend of JPY 0.00 against JPY 7.00 a year ago.

Latest news about Sumitomo Pharma Co., Ltd.

Lull in Geopolitical Tensions Lifts Asian Stock Markets	Apr. 22	MT
Jefferies Adjusts Sumitomo Pharma’s Price Target to 420 Yen From 520 Yen, Keeps at Hold	Apr. 17	MT
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	Apr. 02	MT
Roivant's anti-inflammatory drug succeeds in mid-stage study	Apr. 02	RE
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	Mar. 17	MT
Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from S&P Japan 500	Mar. 17	CI
Sumitomo Pharma Enters into an Agreement to Amend the Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds Including Ulotaront with Otsuka	Mar. 15	CI
US Inflation Report Lifts Asian Stock Markets	Mar. 01	MT
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	Feb. 16	MT
Japan's Nikkei slips after Fed chair signals delay in rate cut	Jan. 31	RE
Transcript : Sumitomo Pharma Co., Ltd., Q3 2024 Earnings Call, Jan 31, 2024	Jan. 31
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	Jan. 31	CI
Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	Jan. 31	CI
Fed, China Property Outlooks Roil Asian Stock Markets	Jan. 30	MT
Japan's Nikkei rounds off 2023 with biggest yearly gain in a decade	Dec. 29	RE
Interest Rates, China Housing Measures Lift Asian Stock Markets	Dec. 15	MT
China Real Estate, FX Roil Asian Stock Markets	Nov. 29	MT
Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®	Nov. 02	CI
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis	Nov. 02	CI
Japanese Shares End Higher on Tuesday After BOJ Kept Rate Unchanged; Shares of Nippon Electric Glass Jump Over 10%	23-10-31	MT
Sumitomo Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2023	23-10-31	CI
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024	23-10-31	CI
Flat China Price Report Dulls Asian Stock Markets	23-10-13	MT
Poxel: losses widen, share price falls	23-09-26	CF
Japan stocks retreat from 33-year peak ahead of Fed policy decision	23-09-20	RE

Chart Sumitomo Pharma Co., Ltd.

Duration

Period

More charts

Company Profile

Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment; - other (7.1%): veterinary drugs, food additives, industrial chemical products, etc. Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).

Sector

Pharmaceuticals

Calendar

2024-05-13 - Q4 2023 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Sumitomo Pharma Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

410 JPY

Average target price

333.8 JPY

Spread / Average Target

-18.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SUMITOMO PHARMA CO., LTD.	-12.02%	1.03B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals